Siemens Healthineers Presentation
Total Page:16
File Type:pdf, Size:1020Kb
COVID-19 Response Portfolio Overview April, 2020 www.corporate.siemens-healthineers.com/covid-19 Unrestricted © Siemens Healthineers, 2020 We are in this together – Our response to the COVID-19 pandemic We are fully committed to supporting our partners throughout the healthcare system to provide the best possible care for patients. The coronavirus (SARS-CoV-2) pandemic continues to spread, confronting healthcare professionals around the world with unprecedented clinical and operational challenges. As they struggle to deal with this extraordinary situation, at the same time they must also continue to care for other patients. At Siemens Healthineers, we are aware of the urgency and complexity of the current situation, and we are working hard to provide the best possible support to healthcare providers at each stage of COVID-19 patient care: diagnosis, prognosis, therapy and follow-up. Our aspiration to drive innovations forward so people live healthier and longer lives is more valid today than ever before. We are stepping up as a partner to support healthcare systems helping them to deliver high-value care to patients and families. Please do not hesitate to contact us in case of questions or suggestions. Due to high demand, availability in certain regions may be affected, please contact your local Siemens Healthineers organization for details. 2 Unrestricted © Siemens Healthineers, 2020 COVID-19 patient pathway1 3 1) This pathway is for illustration purposes only. Unrestricted © Siemens Healthineers, 2020 We support you to provide the best possible care for patients In the following overview we want to highlight parts of the portfolio from Siemens Healthineers that can support healthcare providers at each stage of coronavirus (SARS-CoV-2) patient care: diagnosis, prognosis, therapy and follow-up. Clinical Our medical imaging, laboratory diagnostics and point-of-care testing solutions can support physicians to make a prognosis about the severity of a COVID-19 case, help treat the patient, and assist in the follow-up to find out when the patient has recovered. Operational At the same time our digital health solutions, services and consulting can support healthcare providers in protecting healthcare workers and increasing healthcare delivery capacity. For example, our digital services enable medical personnel to operate systems regardless of their location and thus with a potentially lower risk of infection. Diagnosis Prognosis Therapy Follow-up Clinical Operational 4 Unrestricted © Siemens Healthineers, 2020 Clinical Click to add footnote 5 second line Unrestricted © Siemens Healthineers, 2020 Molecular testing for the specific identification of the coronavirus (SARS-CoV-2) causing COVID-19 Identification of the coronavirus causing COVID-19 Robust, highly sensitive molecular testing is critical for the identification of the coronavirus causing COVID-19. Real-time PCR testing amplifies the RNA from SARS-CoV-2, enabling specific identification so medical teams can address the COVID-19 pandemic in their molecular research labs. The FTD SARS-CoV-2 Assay The FTD SARS-CoV-2 Assay (RUO)1 will utilize the same workflow, including PCR profile, as existing Fast Track Diagnostics (FTD) Respiratory Disease kits. The FTD SARS-CoV-2 Assay (RUO) was optimized on the Biomerieux EasyMag Extraction System and the Applied Biosystems 7500 Real-time PCR Thermocycler, which are used in clinical laboratories worldwide. Healthcare providers are encouraged to optimize the assay on additional instruments to increase the availability of testing around the world. 1) For Research Use Only (RUO). Pursuing FDA Emergency Use Authorization (EUA). Pursuing WHO Emergency Use Assessment and Listing (EUAL) certification. 6 Product availability varies by country Unrestricted © Siemens Healthineers, 2020 Immunoassay and chemistry lab tests help assess severity and manage comorbidities in COVID-19 patients Assess severity and manage comorbidities in COVID-19 patients Once COVID-19 is detected, immunoassay and chemistry laboratory tests play a critical role in assessing disease severity and managing comorbidities. Since patients with comorbidities are at greater risk of complications, tests might include (but are not limited to) troponin and natriuretic peptides for cardiovascular disease, blood Place released glucose for diabetes, and creatinine and eGFR for kidney disease. portfolio picture here Immunoassay and Chemistry Analyzers and Assays The Atellica® Solution and ADVIA Centaur® Analyzers have broad assay menus to help assess COVID-19 infection severity and manage comorbidities; and, the easy-to-install Dimension® EXL 200 Integrated Chemistry System can help mobilize testing quickly in pop-up labs. We are expanding our infectious-disease testing capabilities to address the COVID-19 pandemic. To that end, Siemens Healthineers is developing a SARS-CoV-2 serology assay1 and is also exploring potential partnerships to help address the COVID-19 pandemic. 7 1) In development; not available for sale. Future availability cannot be guaranteed. Unrestricted © Siemens Healthineers, 2020 Hemostasis and Hematology testing in the identification of severe COVID-19 infections Identification of blood abnormalities Hemostasis and Hematology testing identify abnormalities in the blood and help to assess the severity of COVID-19 patients, including disease classification and treatment grading; they can be a strong predictor of adverse outcomes.1-3 Scalable hemostasis and hematology solutions Siemens Healthineers offers a broad selection of hemostasis and hematology testing solutions to support physicians in making sound diagnostic and therapeutic decisions. The ADVIA® Hematology and Sysmex® Hemostasis systems provide the scalability needed for accurate testing in both low and high-volume testing environments. 1) Tan, L., Wang, Q., Zhang, D. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther 5, 33 (2020). https://doi.org/10.1038/s41392-020-0148-4 2) Huang, C., Wang, Y., Li, X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 10223 (2020). https://doi.org/10.1016/S0140-6736(20)30183-5 3) Zhou F, Lancet 2020; Huang C, Lancet 2020; Zhang JJ, Allergy 2020; Tang N, J Thromb Haemost 2020; Gao Y, J Med Virol 2020; Lippi G, Clin Chem Lab Med. 2020; Wang D, J Am Med Assoc 2020; Han, Clin Chem Lab Med 2020; Tang et al., J Thromb Haemost 2020 8 Product availability varies by country Unrestricted © Siemens Healthineers, 2020 Blood gas systems are used in the management of ventilated patients under respiratory distress Blood gas testing is often required for patients undergoing evaluation for respiratory distress and/or signs of dyspnea These conditions are caused by various diseases that affect breathing. The COVID-19 infection (SARS-CoV-2) is one such disease. Arterial blood gas (ABG) tests measure pH (acidity and alkalinity) and the levels of oxygen (pO2) and carbon dioxide (pCO2). The ABG test provides a status of the patient’s oxygenation levels, enabling caregivers to determine if adjustments to ventilator settings or other treatments are required. Blood Gas Solutions from Siemens Healthineers The RAPIDPoint® 500e Blood Gas System and epoc® Blood Analysis System are important analyzers supporting COVID-19 response efforts, where blood gas testing plays a critical role in managing infected patients and monitoring their respiratory distress. The analyzers integrate seamlessly into hospital networks with the Point of Care Ecosystem™, which offers remote management of operators and devices. 9 Product availability varies by country. Unrestricted © Siemens Healthineers, 2020 Computed Tomography (CT) helps to evaluate COVID-19 patients and survey their progression Evaluation of pneumonia with CT High resolution chest CT images help assess the severity of the lung involvement in COVID-19 patients, especially those with severe symptoms. This includes evaluation of the progression and remission of the disease.1 CT with SOMATOM go. platform Scanners from the SOMATOM go. platform2 are recommended for fast delivery requests in areas where COVID-19 is prevalent. The unique mobile CT workflow of SOMATOM go. platform scanners permits technologists to maintain a distance of at least 1.5 m (5 ft) from potentially infected patients. Tin Filter technology is available in all our scanners offering radiation exposure control when surveying the patient’s progression.3 These scanners can also be installed in mobile units to provide access in high-demand or in isolated areas. 1) Fang et al., Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR, Radiology 2020 2) Mainly SOMATOM go.Up, SOMATOM go.All, SOMATOM go.Top 10 3) Kang et al., Recommendation of low-dose CT in the detection and management of COVID-19 Unrestricted © Siemens Healthineers, 2020 Radiography supports the initial assessment of severity and monitoring of lung involvement of COVID-19 patients Evaluation of pneumonia with radiography Radiography supports initial assessment of severity and monitoring of disease progression. Chest radiographs can show characteristic signs of viral acquired pneumonia. Typical radiographic findings include airspace opacities, ground-glass opacity (GGO), and consolidation. Radiography with MULTIX Impact MULTIX Impact is a flexible, modular radiography system which covers a wide range of clinical requirements. Siemens Healthineers offers specific solutions for deployment in temporary COVID-19